Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.47 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 4/20 | 0.31 |
| ▸ | RICTOR | Q6R327 | 4/20 | 0.31 |
| ▸ | MAPKAP1 | Q9BPZ7 | 4/20 | 0.31 |
| ▸ | MLST8 | Q9BVC4 | 4/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689522 | 1.00 | PLK1 (0.47) | PLK1PLK2PLK3MTORRICTOR | |
| SCHEMBL1688433 | 0.89 | PLK1 (0.45) | PLK1PLK2PLK3 | |
| SCHEMBL1688426 | 0.88 | PLK1 (0.47) | PLK1PLK2PLK3MTORRICTOR | |
| SCHEMBL2688787 | 0.88 | PLK1 (0.47) | PLK1PLK2PLK3MTORRICTOR | |
| SCHEMBL2048059 | 0.83 | PLK1 (0.60) | PLK1PLK2PLK3MTORRICTOR | |
| SCHEMBL2048055 | 0.83 | PLK1 (0.60) | PLK1PLK2PLK3MTORRICTOR | |
| SCHEMBL2052447 | 0.83 | PLK1 (0.60) | PLK1PLK2PLK3MTORRICTOR | |
| SCHEMBL2690643 | 0.82 | PLK1 (0.44) | PLK1PLK2MTORRICTORMAPKAP1 | |
| SCHEMBL2688176 | 0.82 | PLK1 (0.44) | PLK1PLK2MTORRICTORMAPKAP1 | |
| SCHEMBL2688229 | 0.81 | PLK1 (0.47) | PLK1PLK2PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | PLK1 1/4885PLK2 19/4885PLK3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.